Tirzepatide

In human trials

• See source wording

  under the skin · every 4 weeks · for 36 weeks

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight LossPHASE3 · NCT04660643

  “Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg..”

• See source wording

  Tirzepatide for Alcohol Use DisorderPHASE2 · NCT06994338

  “Tirzepatide injections (2.5mg, 5.0mg).”

• See source wording

  under the skin · once a week

  A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesPHASE3 · NCT03861039

  “5 mg Tirzepatide.”

• See source wording

  under the skin · weekly

  A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightPHASE3 · NCT06131437

  “CagriSema 2.4 mg/2.4 mg.”

• See source wording

  under the skin · weekly · for 12 months

  Tirzepatide for Treatment of CCCAPHASE2 · NCT07734870

  “Participants will receive 2.5 mg once weekly for the first 4 weeks, followed by 5 mg once weekly for the remainder of the 12-month treatment period.”

• 15 mg

  under the skin · weekly

  Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With ObesityPHASE4 · NCT06009653

  “Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week..”

• See source wording

  under the skin · every 4 weeks · for 52 weeks

  Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaPHASE3 · NCT05412004

  “Participants not on positive airway pressure (PAP) therapy received a maximum tolerated dose (MTD) of 10 milligrams (mg) or 15 mg of Tirzepatide once weekly (QW) as a subcutaneous (SC) injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks.”

• See source wording

  under the skin · every 4 weeks · for 76 weeks

  Tirzepatide Use in People With Obesity and Type 1 DiabetesPHASE4 · NCT07096908

  “Starting dose will be 2.5mg and dose will be increased gradually, by increments of 2.5mg, every 4 weeks to reach 15 mg at week 24 based on patient's tolerability of side effects (i.e.”

• 15 mg

  weekly

  Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use DisorderPHASE2 · NCT06939088

  “Tirzepatide once-weekly s.c.titrated to a maximum dose of 15 mg.”

• See source wording

  under the skin · weekly

  Effects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsPHASE2 · NCT06811324

  “Once weekly tirzepatide starting at 2.5 mg/weekly, with dose escalation monthly by 2.5 mg to a target dose of 10 mg/weekly or maximum tolerated.”

• See source wording

  under the skin · for 16 weeks

  Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatidePHASE4 · NCT06657209

  “16 weeks started at 2.5mg/week and increased to 5mg/week dose.”

• See source wording

  under the skin · weekly · for 52 weeks

  A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesPHASE3 · NCT03861052

  “5 mg Tirzepatide.”

• See source wording

  Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)PHASE1 · NCT07559500

  “Radiotracer injection of \[11C\]raclopride during combined PET/MR scan to measure striatal dopamine release (Methylphenidate 0.25 mg/kg injected 45 minutes post radiotracer injection).”

• See source wording

  weekly

  Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTsNA · NCT07589322

  “Starting at Tirzepatide 2.5 mg weekly and escalated as tolerated to 10 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials..”

• See source wording

  under the skin · once a week

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)PHASE2 · NCT04166773

  “5 mg Tirzepatide.”

• See source wording

  under the skin · every 4 weeks · for 4 weeks

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightPHASE3 · NCT04184622

  “5 mg Tirzepatide.”

• See source wording

  under the skin · every 4 weeks · for 4 weeks

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesPHASE3 · NCT05822830

  “15 mg or MTD - Tirzepatide.”

• See source wording

  under the skin · every 4 weeks · for 28 weeks

  Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With ObesityPHASE2 · NCT07228741

  “A once-weekly subcutaneous injection starting at 2.5 mg and dose escalation every 4 weeks up to a maximum of 15 mg, following FDA-approved guidelines.”

• See source wording

  under the skin · weekly

  A Study of Tirzepatide (LY3298176) in Pediatric Participants With ObesityPHASE1 · NCT05696847

  “Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg).”

• 5 mg

  under the skin · twice daily · for 12 weeks

  Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor AgonistsNA · NCT07619989

  “Participants will receive active transcutaneous auricular vagus nerve stimulation plus tirzepatide 5 mg for 12 weeks.”

• See source wording

  under the skin · every 4 weeks

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPHASE3 · NCT04255433

  “Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered as subcutaneous (SC) injection once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years..”

• See source wording

  under the skin · every 4 weeks · for 72 weeks

  A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramPHASE3 · NCT04657016

  “Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg..”

• 2.5 mg

  under the skin

  Tirzepatide for the Treatment of Cannabis Use DisorderPHASE2 · NCT07265752

  “2.5mg subcutaneous injection once.”

• See source wording

  by mouth · daily

  A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female ParticipantsPHASE1 · NCT04172987

  “Participants received a 28-day packet of a combination oral contraceptive (OC) containing 21 days of tablets that consist of active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD) on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day..”

• See source wording

  under the skin

  A Study of Tirzepatide (LY3298176) in Healthy ParticipantsPHASE1 · NCT03375463

  “5 mg Tirzepatide SC (Solution)-Part A.”

• See source wording

  under the skin · weekly

  A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightPHASE3 · NCT04657003

  “10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW).”

• 2.5 mg

  under the skin · weekly · for 24 weeks

  Tirzepatide to Slow Biological AgingPHASE2 · NCT07220473

  “Auto injectors with a 2.5 mg dosage are given subcutaneously weekly..”

• See source wording

  daily

  Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityPHASE2 · NCT05933499

  “SQ bimagrumab 300mg qweek.”

• See source wording

  weekly · for 4 weeks

  Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol SecretionPHASE2 · NCT07573163

  “Tirzepatide will be initiated at the lowest dose of 2.5 mg once weekly for 4 weeks.”

• See source wording

  weekly

  Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesPHASE3 · NCT06246799

  “Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated..”

• See source wording

  for 4 weeks

  A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young AdultsNA · NCT07364175

  “2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks.”

• See source wording

  under the skin

  A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 DiabetesPHASE1 · NCT03322631

  “Participants received escalating doses of 2.5 milligrams (mg), 5 mg, 10 mg and 15 mg of tirzepatide administered into the subcutaneous (SC) tissue of the abdominal wall..”

• See source wording

  under the skin · once a week

  A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AlonePHASE3 · NCT03954834

  “5 mg Tirzepatide.”

• See source wording

  under the skin · once a week · for 10 days

  A Study of Tirzepatide in Overweight and Very Overweight ParticipantsPHASE1 · NCT04311411

  “Participants received tirzepatide 5 milligrams (mg) once a week (QW) for Weeks 1 through 3 followed by tirzepatide 10 mg QW for Weeks 4 through 6 into the subcutaneous (SC) tissue of the abdominal wall..”

• See source wording

  under the skin · weekly

  Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVPHASE2 · NCT06935838

  “An initial dose of TZP 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg..”

• 2.5 mg

  under the skin · weekly · for 3 months

  2024 Tirzepatide-Bariatric SurgeryPHASE4 · NCT06721507

  “Participants will self inject 2.5 mg tirzepatide subcutaneously once weekly and maintain a drug administration diary.”

• See source wording

  under the skin · weekly · for 12 weeks

  GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 DiabetesPHASE3 · NCT06630585

  “Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.”

• 2.5 mg

  once a week

  The Long COVID Treatment TrialPHASE2 · NCT07128082

  “The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week..”

• 5 mg

  under the skin

  A Study of Tirzepatide at Different Injection Sites in Participants With Different Body SizesPHASE1 · NCT04050670

  “Participants received 5mg Tirzepatide by subcutaneous injection on upper arm..”

• See source wording

  under the skin · every 4 weeks · for 40 weeks

  A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)PHASE4 · NCT05564039

  “The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5mg to 15 mg) until 15 mg or MTD was reached..”

• See source wording

  every 3 weeks

  Tirzepatide in the Treatment of Cannabis Use DisorderPHASE3 · NCT07671248

  “Treatment will occur over a 12-week period, with once-weekly injections of escalating doses every 3 weeks from 2.5mg to 10mg.”

• See source wording

  every 4 weeks

  LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide TherapyNA · NCT06885736

  “The aim of this arm of the intervention is to ensure a protein intake of 1.6g/kg/day, as this was the intake level identified as the level after which no further effect was found on muscle mass in the meta-regression from (Morton et al., 2018).”

• See source wording

  Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialPHASE2 · NCT07676331

  “3 weeks of neoadjuvant letrozole 2.5 mg/d.”

• See source wording

  under the skin · every 4 weeks · for 12 weeks

  Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese PatientsPHASE4 · NCT07715929

  “Titrated from 2.5 mg/week to a target of 10 mg/week over 12 weeks, then maintained at the maximum tolerated dose for the remainder of the 52-week treatment period..”

• See source wording

  under the skin · every 4 weeks · for 20 weeks

  An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderPHASE2 · NCT07693608

  “Following the instructions of the FDA-approved prescribing label, the dosing schedule will include a 4-week titration at a starting dosage of 2.5mg/week.”

• See source wording

  under the skin · weekly

  TIRzepatide for the Treatment of Obesity in Patients With Atrial FibrillationPHASE2 · NCT06802081

  “Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated..”

• See source wording

  weekly

  Effect of Tirzepatide on Diabetic Peripheral Sensorimotor NeuropathyPHASE4 · NCT07706088

  “Tirzepatide 2.5mg weekly.”